Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Zai Lab Ltd - ADR - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ZLAB
Nasdaq
2834
https://www.zailaboratory.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Zai Lab Ltd - ADR
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
- Apr 15th, 2024 11:30 am
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
- Apr 11th, 2024 11:30 am
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
- Apr 2nd, 2024 11:30 am
Shareholders in Zai Lab (NASDAQ:ZLAB) are in the red if they invested three years ago
- Apr 1st, 2024 3:28 pm
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
- Apr 1st, 2024 11:30 am
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
- Mar 27th, 2024 1:29 pm
Shhh! 7 Small-Cap Stocks That Can Double by 2025
- Mar 20th, 2024 8:30 pm
Chief Legal Officer Edmondson Frazor Titus III Sells 10,000 Shares of Zai Lab Ltd (ZLAB)
- Mar 19th, 2024 11:01 pm
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
- Mar 13th, 2024 11:05 pm
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
- Mar 6th, 2024 9:01 pm
Zai Lab Announces Participation in March Investor Conference
- Mar 6th, 2024 12:30 pm
Zai Lab Limited (NASDAQ:ZLAB) Q4 2023 Earnings Call Transcript
- Feb 29th, 2024 1:51 pm
Zai Lab Ltd (ZLAB) Reports 25% Year-Over-Year Revenue Growth in Full-Year 2023 Financial Results
- Feb 27th, 2024 9:38 pm
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
- Feb 27th, 2024 9:05 pm
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
- Jan 25th, 2024 9:15 pm
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
- Jan 10th, 2024 10:12 pm
Zai Lab Ltd Chairperson & CEO Ying Du Sells 8,380 Shares
- Jan 5th, 2024 12:02 am
What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock
- Dec 22nd, 2023 5:00 pm
Zai Lab Announces Participation in January Investor Conference
- Dec 19th, 2023 12:30 pm
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
- Dec 13th, 2023 1:53 pm
Scroll